ScreenerHero

VERU Veru Inc.

NAS · US · Healthcare · Biotechnology · verupharma.com
2.460USD-0.40%Mkt Cap: 41.94M $P/E: —

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and inter…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap41.94M USD
Enterprise Value19.06M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-22.73M USD
Revenue/Share—
Last Price2.460 USD
Fiscal Year EndSep 2025
MR QuarterJun 2026
Employees20
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.70
PEG3.60
EV/EBITDA-0.69
EV/Revenue—
P/S—
P/B1.48
EPS (TTM)-0.59
EPS (Forward)-0.92
52W Range
2.0508% of range7.330
52W High7.330 USD
52W Low2.050 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-123.97%
ROA-76.17%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-30.04M USD
CapEx (TTM)1.08K USD
FCF Margin—
FCF Yield-34.44%
Net Debt-23.05M USD
Net Debt/EBITDA0.83
Balance Sheet
Debt/Equity0.17
Current Ratio4.42
Quick Ratio4.18
Book Value/Sh1.66 USD
Cash/Share1.51 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield3.58%
Payout Ratio0.00%
Ex-Div DateApr 28, 2014
Pay DateMay 7, 2014
Splits
Last Split1:10
Split DateAug 11, 2025
Analyst Consensus
Rating—
Target (Mean)24.50 USD
Upside (mean)+895.9%
Target Range24.00 USD – 25.00 USD
24.00+895.9% to mean25.00
# Analysts2
Ownership
Shares Out.17.05M
Float15.48M
Insiders9.22%
Institutions19.64%
Short Interest
Short Ratio6.8d
Short % Float9.73%
Short % Out.8.84%
Shares Short1.51M
Short (prev mo.)1.40M
Technical
SMA 502.528 (-2.7%)
SMA 2002.495 (-1.4%)
Beta-1.20
S&P 52W Chg16.45%
Avg Vol (30d)224.65K
Avg Vol (10d)239.63K
Technical Indicators
RSI (14)45.8
MACD-0.0114
MACD Signal-0.0096
MACD Hist.-0.0018
BB Upper2.669 USD
BB Middle2.500 USD
BB Lower2.331 USD
BB Width13.53%
ATR (14)0.1325 USD
Vol Ratio (20d)0.78x